PMID: 7013963Mar 1, 1981Paper

Adjuvant immunotherapy of high risk stage I melanoma with transfer factor

Cancer
M R BlumeE Shepley

Abstract

Following conventional surgical management, 100 patients with high risk Stage I melanoma were treated with transfer factor to reduce the incidence of disease recurrence. All patients had primary lesions invasive to Clark's level III or deeper and exceeding 1.0 mm in measured thickness. Ninety-six patients are available for analysis at 15 to 67 months (median: 30 months) after diagnosis. Nine patients have had a recurrence of disease (treatment failure), and one has died. Actuarial non-failure rate is 90%, and survival rate is 99% at five years. A nonrandomized but contemporary control group of 46 patients displaying comparable risk factors was treated with surgery alone. The non-failure rate of this group is 63%, and the survival rate is 69%, data consistent with the results of several published studies. These results suggest that transfer factor immunotherapy may be a valuable adjunct in the treatment of patients with high risk Stage I melanoma.

References

Sep 22, 1977·The New England Journal of Medicine·U VeronesiN N Trapeznikov
May 1, 1976·Current Problems in Surgery·N C Davis
Mar 19, 1976·Deutsche medizinische Wochenschrift·J TonakF Weidner
Aug 1, 1976·The Australian and New Zealand Journal of Surgery·N DavisJ Little
Jan 29, 1976·The New England Journal of Medicine·F R EilberK P Ramming
Mar 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·B DupontR A Good
Jun 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·H F OettgenL Thomas
Oct 1, 1974·American Journal of Surgery·M G Hansen, A B McCarten
Jan 24, 1974·The New England Journal of Medicine·E A Gehan, E J Freireich
Oct 1, 1974·Cancer·A F LoBuglio, J A Neidhart
Apr 26, 1973·The New England Journal of Medicine·B R Bloom
Jan 1, 1974·Annals of Surgery·S L Gumport, M N Harris
Jan 1, 1969·Advances in Immunology·H S Lawrence
Jul 1, 1965·Annals of Surgery·E D MUNDTHJ W RAKER
Aug 1, 1965·American Journal of Surgery·J H MEHNERT, J L HEARD

❮ Previous
Next ❯

Citations

Jan 1, 1996·Biotherapy·C Fernandez-OrtegaM J Araña
Oct 26, 2002·Critical Reviews in Oncology/hematology·R Molife, B W Hancock
Aug 1, 1990·The British Journal of Dermatology·V SteinkrausC Körner
Mar 1, 1992·The Annals of Thoracic Surgery·R I WhyteM M Kirsh
Apr 1, 1984·Journal of Surgical Oncology·L J HumphreyF J Volenec
Jan 1, 1985·Medical and Pediatric Oncology·H K KohR W Carey
Aug 1, 1984·The Australian and New Zealand Journal of Surgery·P Hersey, C M Balch

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.